Global Transdermal Drug Delivery Partnering Deals Analysis 2010-2015

Sep 23, 2015, 10:10 ET from Research and Markets

DUBLIN, Sept. 23, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Global Transdermal Drug Delivery Partnering 2010-2015" report to their offering.

Transdermal Drug Delivery Partnering 2010-2015 provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter transdermal drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 150 links to online copies of actual transdermal drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report scope:

This data driven report includes:

  • Trends in transdermal drug delivery dealmaking in the biopharma industry since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 150 transdermal drug delivery actual deal records
  • The leading transdermal deals by value since 2010

In Transdermal Drug Delivery Partnering 2010-2015, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Therapy type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in transdermal drug delivery dealmaking

Chapter 3 - Average financial deal terms for transdermal drug delivery partnering

Chapter 4 - Leading transdermal drug delivery deals

Chapter 5 - Transdermal drug delivery partnering dealmaking directory

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets